Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901488 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5901872 | 0.93 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5965177 | 0.93 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5965244 | 0.92 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5965125 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5901345 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6185941 | 0.86 | LMNA (0.37) | — | |
| SCHEMBL6258629 | 0.86 | LMNA (0.40) | CYP3A4CYP2C9 | |
| SCHEMBL5965113 | 0.85 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6256787 | 0.85 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001909-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1406898-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030176447-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176447-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | CYP1A2 849/4885CYP3A4 729/4885CYP2C9 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.